Shots:

• Immatics to receive ~$50M up front for two initial programs & ~$550M as milestones/ product along with royalties. Immatics is eligible to receive option- milestones and royalties on each additional program
• GSK to get access to two Immatic’s TCR-T programs and will get an option to select additional targets to include in the collaboration. The collaboration will initially focus on developing autologous T-cell therapies with an option to add allogeneic cell therapies using Immatics’ ACTallo approach
• Immatics will be responsible for the development of TCR therapies up to clinical- later GSK will be responsible for further development & commercialization. The companies may co-develop one or more TCR therapies including the conduction of first-in-human clinical studies

Click here ­to­ read full press release/ article 

Ref: Businesswire | Image: GSK